Loss of transferrin receptor activity in Neisseria meningitidis correlates with inability to use transferrin as an iron source. by Tsai, Joyce et al.
Vol. 56, No. 12INFECTION AND IMMUNITY, Dec. 1988, p. 3132-3138
0019-9567/88/123132-07$02.00/0
Copyright © 1988, American Society for Microbiology
Loss of Transferrin Receptor Activity in Neisseria meningitidis
Correlates with Inability To Use Transferrin as an Iron Source
JOYCE TSAI,* DAVID W. DYER,t AND P. FREDERICK SPARLING
Department of Microbiology and Immunology, University of North Carolina School of Medicine,
Chapel Hill, North Carolina 27599
Received 1 July 1988/Accepted 5 September 1988
Although Neisseria meningitidis does not produce siderophores, it is able to obtain iron from human
transferrin. We observed saturable specific binding of 125I-labeled human transferrin to meningococci. Human
lactoferrin and mouse transferrin did not compete with human transferrin for binding, whereas human
apotransferrin and 100% iron-saturated transferrin competed equally well. Meningococci thus have a specific
receptor for human transferrin. Scatchard analysis yielded a relatively low Kd of 0.7 ,uM and an apparent copy
number of 2,900 receptors per CFU. Receptor activity was iron-regulated. A meningococcal transformant
specifically unable to utilize transferrin as an iron source had decreased transferrin receptor activity. These
data are consistent with the hypothesis that receptor-mediated binding of transferrin is a rate-limiting step in
meningococcal iron uptake from transferrin.
Neisseria meningitidis is a pathogen for which humans are
the only host. Most of the available iron (Fe) in the body is
stored in iron-binding proteins; in serum the principal Fe
source is transferrin (TF), and on mucosal surfaces the
principal Fe source is lactoferrin (LF) (5, 17). Successful
pathogens have evolved mechanisms by which they obtain
Fe from TF and LF (32). Most bacteria accomplish this by
production of iron chelators, termed siderophores (20, 21,
25). The pathogenic Neisseria species, however, are unusual
in their inability to produce siderophores (22, 28, 33). Nev-
ertheless, meningococci can use TF in vitro as the sole Fe
source (19). Virulence in mice is enhanced by subjecting
meningococci to Fe-limited conditions prior to infection (4)
and by injecting mice with Fe-TF prior to infection (11, 12).
These data suggest that the ability to use Fe-TF is necessary
for growth in vivo.
The mechanism by which meningococci scavenge Fe from
TF is unknown but may be similar to receptor-mediated
mechanisms postulated for a few other human pathogens
(28). The binding of LF but not TF to the surface of
Trichomonas vaginalis suggests the presence of a specific
LF receptor (23). Bordetella pertussis binds LF and TF in a
manner consistent with the presence of specific receptors
(24). An LF receptor of Mycoplasma pneumoniae has been
partially characterized (29). Evidence for a TF receptor on
meningococci includes the observation that meningococci
cannot utilize TIF as an Fe source when TF is sequestered in
a dialysis bag; contact appears to be necessary (1, 28).
Simonson et al. (28) demonstrated that human TF would
bind to meningococci but did not demonstrate the saturable
specific binding characteristic of a receptor. Recently,
Schryvers and Morris (27) showed that horseradish peroxi-
dase-conjugated human TF (HRP-TF) bound to meningo-
cocci immobilized on nitrocellulose in a solid-phase assay;
binding was both saturable and specific.
We have used a classical receptor-binding assay to evalu-
ate the affinity, specificity, and copy number of the meningo-
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coccal TF receptor. We also demonstrate the biological
importance of receptor function through the use of mutants
specifically unable to use TF for growth.
MATERIALS AND METHODS
Strains, media, and growth conditions. N. meningitidis
FAM30 is a nalidixic acid-resistant (Nalr) spectinomycin-
resistant (Spcr) derivative of the wild-type serogroup C
serotype 2a parent strain FAM18 (8). FAM30 is wild type in
its ability to use Fe from ferric dicitrate complexes, TF, LF,
heme, and hemoglobin. FAM38 is a fud-6 hga-J transform-
ant of FAM30; FAM38 is specifically unable to use TF as the
sole source of required Fe for growth (TF-) and lacks 85-
and 95-kilodalton (kDa) outer membrane FeRPs (Fe-re-
pressible proteins) produced by FAM30. FAM41 is a related
transformant of FAM30 that carries only thefud-6 mutation;
FAM41 also is TF- but has wild-type outer membrane
protein profiles. These strains were described recently (8).
Strain M986-NCV-1 is a nonencapsulated derivative of se-
rogroup B N. meningitidis M986 (10); it was provided by C.
Frasch and is designated FAM2 in this paper. FAM11 is a
mutant of FAM2 unable to use TF, LF, ferric dicitrate, or
aerobactin as Fe sources and lacks a 70-kDa FeRP. FAM63
is a revertant of FAM11 that has partially recovered its
ability to use TF without regaining the 70-kDa FeRP (9).
Meningococci were routinely cultured on GCB agar (Difco
Laboratories, Detroit, Mich.) containing Kellogg supple-
ments I and 11 (14) at 37°C in a 5% CO2 atmosphere. To
Fe-deplete cells, we used a low-Fe, Chelex-treated defined
medium (CDM) (34). Control (Fe-sufficient) cells were ob-
tained from cultures in CDM supplemented with 10 ,uM
ferric nitrate. Cell growth was measured by optical density
with a Klett-Summerson colorimeter with a green filter. All
glassware was acid-washed to remove contaminating Fe
(19).
Iron sources. Human TF purchased from Sigma Chemical
Co., St. Louis, Mo., was at least 98% pure by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and significantly Fe-free, according to the supplier.
Human LF was the gift of S. V. Pizzo (Duke University
Medical Center) and was approximately 95% pure as deter-
mined by SDS-PAGE. Mouse TF was obtained from Chem-
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icon International, El Segundo, Calif. Preparation of Fe- and
55Fe-loaded forms of these proteins has been described
elsewhere (19). All Fe-binding proteins used in these exper-
iments were 100% Fe saturated except apotransferrin
(apoTF). HRP-TF was obtained from Jackson Immunore-
search Laboratories, Avondale, Pa.
ApoTF was made by dialyzing TF overnight against two
changes of 50 mM sodium acetate-150 mM sodium chloride
(pH 5.0) buffer containing 100 ,uM desferroxamine mesylate
(Desferal; Ciba Pharmaceutical). The TF was renatured by
dialysis overnight versus 40 mM Tris-20 mM sodium bicar-
bonate-150 mM sodium chloride (pH 7.4) containing 10 g of
Chelex-100 per liter (Bio-Rad Laboratories, Richmond,
Calif.). 125I-TF was made from 100% Fe-saturated human TF
by the method of Markwell (16). A 500-,ug sample of TF was
added to 1 mCi of carrier-free Na1251 (Amersham Corp.,
Arlington Heights, Ill.) and two lodo-beads (N-chloro-ben-
zenesulfonamide [sodium salt]-derivatized uniform nonpo-
rous polystyrene beads; Pierce Chemical Co., Rockford, Ill.)
in 500 ,ul of 100 mM sodium phosphate buffer (pH 7.0). The
reaction was allowed to proceed for 5 min at room temper-
ature with agitation. Unincorporated 1251 was removed by
passing the 125I-TF down a Sephadex G-25 column (Phar-
macia, Inc., Piscataway, N.J.) preblocked with bovine se-
rum albumin (BSA) and equilibrated with 40 mM Tris-20
mM sodium bicarbonate-150 mM sodium chloride (pH 7.4).
The ability of 125I-TF to donate Fe and supp-ort growth was
tested by growing FAM30 in CDM plus 1 puM 125I-TF, 1 ,uM
unlabeled TF, or no added iron source. Purity of I251-TF was
assessed by SDS-PAGE on 10% Laemmli gels (15) and
autoradiography.
Transferrin-binding assays. Fe-replete cells grown over-
night on GCB agar plates were suspended in CDM broth and
grown for two mass doublings; these cells were diluted into
CDM at 37°C and grown for another two mass doublings to
mid-log phase to afford relative Fe depletion. Fe-stressed
cells were harvested at an optical density of 80 Klett units,
pelleted by centrifugation, and suspended in a 0.01 x volume
of CDM containing 1% BSA (CDM-BSA) in BSA-coated
1.5-ml polypropylene Microfuge tubes (Sarstedt, Inc.,
Princeton, N.J.). An equal volume of CDM-BSA was added,
containing 125I-TF and competing ligands where appropriate.
Concentrations of 125I-TF and competitors are indicated
below. Each reaction mixture contained a final volume of
200 RI and about 109 CFU of bacteria. After 20 min, the cells
were pelleted by centrifugation and washed twice by resu-
spension and centrifugation for 1 min in 100 ,lI of CDM-
BSA. After the final resuspension, the cells were transferred
to polystyrene tubes (12 by 75 mm); the amount of cell-
associated 1251I-TF was determined by using a Minoxi -y auto
5000 series gamma counter (Packard Instrument Co., Inc.,
Rockville, Md.). All steps were performed at room temper-
ature to prevent cold-induced cell lysis. Microtubes were
coated with BSA by filling with 2% BSA and agitating for 1
h at room temperature before removing the BSA solution
and drying overnight at 37°C. Specific binding was defined as
the difference between 125I-TF bound in the presence and
absence of a 10Ox concentration of cold TF. 125I-TF used in
specific binding experiments was adjusted to an activity of
500 cpm/pmol. The effect of Fe limitation on binding was
examined similarly by using cells harvested at growth inter-
vals in CDM; by the use of larger culture volumes for
early-phase cultures, cell densities in the binding assays
were constant.
Binding of HRP-TF to cells in a solid-phase dot enzyme
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FIG. 1. Rate of 5"Fe uptake (measured after 10 min) from TF by
Fe-starved FAM30 as a function ofTF concentration. Measurement
of uptake after 30 min revealed higher absolute uptake, but satura-
tion occurred at the same TF concentration. Results depict the
average of two experiments.
by a modified procedure. Cells were harvested after over-
night growth on CDM agar (8) and were suspended to a
density of 30 Klett units in CDM broth. A 50-,lA sample of
each suspension was filtered onto nitrocellulose paper (0.45-
,um BA-85; Millipore Corp., Bedford, Mass.) by using a
96-well filter manifold (Schleicher & Schuell, Inc., Keene,
N.H.). The paper was dried (37°C, 20 min), blocked, probed
with serial dilutions of HRP-TF, washed, and developed
with a chloronaphthol-hydrogen peroxide substrate mixture
(HRP reagent; Bio-Rad) as described previously (27), except
that all incubations were done at room temperature. Devel-
oped blots were scanned by using an ACD-15 densitometer
(Gelman Sciences, Inc., Ann Arbor, Mich.) absorbing at 565
nm.
Western blot assays with HRP-TF were done with modi-
fications of a previously described procedure (27). Cells
were harvested from mid-late-log-phase CDM cultures, and
whole membranes were prepared as described elsewhere
(33). Solubilized membrane proteins (100 pLg) were separated
by SDS-PAGE on 7.5% Laemmli gels (15) and transferred to
nitrocellulose (3). The binding of HRP-TF to proteins on the
Western blot was examined as described for the dot enzyme
assay.
55Fe uptake assays. Log-phase Fe-starved meningococci
were tested for their ability to accumulate 55Fe from 55Fe-TF
by using methods previously described (8).
RESULTS
Concentration dependence of Fe uptake from TF. The
ability of log-phase Fe-starved FAM30 to internalize 55Fe
from 100% Fe-saturated human TF was assayed as a func-
tion of TF concentration (Fig. 1). Uptake of 55Fe increased
linearly up to 1 ,uM TF; little further increase in 55Fe uptake
was noted at TF concentrations above 1 puM. These results
were similar to those noted recently for gonococci (18). They
differ, however, from the saturation of Fe uptake from TF at
30 ,uM observed in meningococcal strain SDIC (28). Reasons
for the discrepancy in results with FAM30 and SDIC are
unclear.
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FIG. 2. (a) Autoradiogram of 1251-TF labeled by the lodo-bead
method and subjected to SDS-PAGE. (b) Growth ofFAM30 in CDM
containing either 1 ,uM 100% Fe-saturated human TF (O), 1 ,uM
251I-TF (A), or no added Fe source (0).
,uM TF
FIG. 3. Specific binding of '25I-TF by FAM30 (0) and FAM38
(A). Specific binding is defined as the difference in the amount of
125I-TF bound in the presence and absence of 100x 100% Fe-
saturated human TF. Results depict the mean and standard devia-
tions for three experiments.
Quality of 25I-TF. We labeled TF with 125I by using
chloramine-T (13), lactoperoxidase-glucose oxidase (6), and
lodo-beads (16). Analysis by SDS-PAGE and autoradiogra-
phy showed that the lodo-bead method produced the least
aggregation and fragmentation of TF (Fig. 2a and data not
shown). Few impurities were detected in the Iodo-bead-
labeled 125I-TF (Fig. 2a). lodinated TF was fully able to
donate Fe to growing meningococci, since FAM30 utilized 1
FM 125I-TF as well as unlabeled TF for growth under
Fe-limiting conditions (Fig. 2b). To further limit radiation-
induced damage, 125I-TF was used within 2 weeks of label-
ing.
Binding of '251-TF. Meningococci bound 1251I-TF in a
saturable specific manner (Fig. 3). Saturation occurred at
approximately 1 ,uM for both FAM30 and FAM38; however,
FAM30 bound four times more TF at this concentration than
did the TF- transformant FAM38. Specific binding data
were subjected to Scatchard analysis (26), which yielded a
Kd of 0.7 ,uM and a copy number of 2,900 receptors per CFU
for FAM30. FAM38 had a similar Kd of 0.4 FM but a
reduced apparent copy number of 560 (Fig. 4). The correla-
tion between the inability of FAM38 to use TF as an Fe
source and the reduced binding of 125I-TF strongly suggests
that the observed TF-binding activity represents a functional
receptor. In control experiments, E. coli HB101 did not bind
125I-TF (data not shown).
Specificity of the meningococcal TF receptor. Competition
experiments were performed to test the specificity of the TF
receptor. Fe-stressed FAM30 cells were incubated with a
constant, saturating concentration of 125I-TF (1 F.M) and
increasing concentrations of mouse TF, human LF, 100%
Fe-saturated human TF, or apoTF. Neither mouse TF nor
human LF displaced the 125I-TF even at 20 times the
concentration of radioligand, although human TF competed
strongly. The ability of apoTF to displace 125I-TF did not
differ significantly from that of 100% Fe-saturated human TF
under these conditions (Fig. 5).
In contrast with our results, a recent report (27) indicates
that apoTF does not compete as effectively as Fe-saturated
TF with HRP-TF for binding to meningococci in a solid-
phase dot enzyme assay. This discrepancy could have arisen
from our use of saturating (1 F.M) concentrations of TF, as
the previous study employed very low concentrations of
HRP-TF (0 to 4 nM). Furthermore, we could not rule out the
possibility that Fe contamination of BSA used to block
nonspecific binding of 125I-TF to Microfuge tubes and me-
ningococcal cells afforded ferration of apoTF. We repeated
the competition experiments using radioligand concentra-
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FIG. 4. Scatchard plot of '25I-TF specific binding to FAM30 (0)
and FAM38 (A) from data shown in Fig. 3. Lines were fitted by
linear regression. Correlation coefficients were -0.845 for FAM30
and -0.701 for FAM38.
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FIG. 5. Binding of 125I-TF (1 ,uM) in the presence of increasing concentrations of 100% Fe-saturated human TF (Oi), apoTF (0), mouse
TF (V), and LF (A). Maximum binding is defined as the amount of '251-TF associated with FAM30 in the absence of competing ligands. Data
shown are the average of two experiments done in duplicate. [X], Concentration of competitor.
desferroxamine. The results were unchanged (Fig. 6) and
suggested that the meningococcal TF receptor bound TF and
apoTF with equal affinity. The solid-phase dot enzyme assay
for HRP-TF binding suggested a diminished ability of apoTF
to compete compared with that of 100% Fe-saturated TF
(data not shown), as reported previously (27). Reasons for
the discrepancy with the two assays are unknown.
Fe-regulated expression of binding. Preliminary binding
studies suggested that receptor activity increased with pro-
gressive Fe starvation (data not shown). Therefore, 1251I-TF
bound to FAM30 and the isogenic TF- strains FAM38 and
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FIG. 6. Binding of 175 nM (0.25 Kd) 125I-TF in the presence of
increasing concentrations of 100% Fe-saturated human TF (O) and
apoTF (0), and 50 ,xM desferroxamine to bind any free Fe.
Desferroxamine was added prior to addition of ligand or competi-
tors. Maximum binding was calculated as shown in Fig. 5. Data
shown are the average values for two experiments done in duplicate.
assayed. Receptor activity of FAM30 dramatically increased
with Fe starvation, whereas FAM38 and FAM41 bound less
TF at all time points (Fig. 7). After six cell doublings,
expression of TF receptor activity continued to increase.
Routine use of cells after four mass doublings in CDM thus
somewhat underestimated maximal TF binding. Even after
six mass doublings, however, the TF- derivatives ofFAM30
still showed little TF binding. We concluded that the TF
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FIG. 7. Binding of 125I-TF as a function of iron starvation. The
amount of 125I-TF bound to FAM30 (0), FAM38 (A), and FAM41
(LJ) was assayed after growth in Fe-depleted CDM; binding was
measured after each doubling in cell mass. Results depict the
average of two experiments done in duplicate.
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FIG. 8. Dot enzyme assay. Binding of serial twofold dilutions of
HRP-TF to Fe-sufficient (+) and Fe-starved (-) FAM30, FAM38,
FAM2, and FAM11. Concentrations of HRP-TF are shown on the
left (,uM).
between FAM30 and either FAM38 or FAM41 were not the
result of delayed expression of receptor activity in FAM38
or FAM41. Results were essentially the same in FAM38 and
FAM41 in these and other experiments (data not shown).
HRP-TF dot assays. Solid-phase assays with HRP-TF as
ligand were also performed to compare FAM30 with FAM38
(Fig. 8). The results were qualitatively similar to those of the
equilibrium-phase assay using 125I-TF: FAM38 bound less
TF than did FAM30, and in both strains TF receptor activity
was increased by Fe starvation. In the same manner, we also
examined the binding of TF to FAM2 and its pleiotropic
Fe-transport mutant FAM11. The inability of FAM11 to
internalize Fe bound to TF, LF, citrate, or aerobactin (9)
suggests that FAM11 probably is altered in a common step
involved in Fe transport, subsequent to or in addition to
specific binding of TF to a receptor. Results showed that
Fe-starved and Fe-sufficient FAM11 bound TF equally and
to the same extent as Fe-starved FAM2 (Fig. 8). The
constitutive expression of TF receptor activity in FAM11
was consistent with earlier evidence that FAM11 is function-
ally Fe starved even when grown in the presence of Fe
because of its inability to internalize Fe (9). Specific binding
of 125I-TF to FAM11 also was equivalent to that observed
with Fe-starved FAM2 in the equilibrium-phase assay (data
not shown). Loss of TF receptor activity thus correlated
very well with the phenotypes of the meningococcal Fe
mutants. Only mutants such as FAM38 that were specifically
unable to use TF were altered in TF receptor activity.
Western blots. Recently, an Fe-regulated meningococcal
membrane protein (about 71 kDa in some strains, 85 kDa in
others) which bound HRP-TF on a Western blot was re-
ported (27), along with the suggestion that this TF-binding
protein (TBP) might be part of a meningococcal TF receptor.
We examined this possibility by determining whether TBP
activity on the Western blot correlated with the results of the
TF-binding assays. Strain FAM30 produced an FeRP of ca.
65 kDa that bound HRP-TF following Western transfer (Fig.
9). Strains FAM38 (Fig. 9) and FAM41 (data not shown)
produced quantities of 65-kDa TBP similar to that in
FAM30, although other assays (Fig. 3, 7, and 8) showed that
these TF- transformants bound significantly less TF to










FIG. 9. Western blot. Binding of HRP-TF to total membrane
proteins of Fe-sufficient (+) and Fe-starved (-) FAM30, FAM38,
FAM2, FAM11, and FAM63. The HRP-TF-binding protein in
FAM30, FAM38, and FAM2 is about 65 kDa.
bound TF normally to whole cells (Fig. 8 and data not
shown), failed to produce significant amounts of 65-kDa TBP
(Fig. 9). These data suggest that 65-kDa TBP is not neces-
sary for functional TF receptor activity.
DISCUSSION
Concentration-dependent saturability and ligand speci-
ficity are two criteria for a biological receptor. Well-charac-
terized eucaryotic receptors recognize only their legitimate
ligand and perhaps those very closely related in structure (2,
7). Specifically bound ligand and should be displaced by an
excess of competing ligand at equilibrium, while nonspecifi-
cally bound ligand should be less readily displaced (2, 7).
Our data confirmed the existence of a receptor for human TF
on the meningococcus, as saturable specific binding and
specificity for human TF were demonstrated for N. menin-
gitidis FAM30. Saturation occurred at 1 ,uM TF, and Scatch-
ard analysis showed a Kd of 0.7 ,uM and a copy number of
2,900 receptors per CFU. The conclusion that these binding
data represent a functional receptor was strengthened by the
demonstration that FAM38, a TF- transformant of FAM30,
was deficient in receptor activity. Scatchard analysis sug-
gested that FAM38 had a receptor of approximately normal
affinity but in reduced apparent copy number. Our data do
not allow determination of whether the TF- allele (fud-6) in
FAM38 altered the TF receptor or altered the cell surface
framework in which the TF receptor is found. The reduction
in TF receptor activity in FAM38 may reflect primary
alteration in other cell surface components, with resulting
steric effects on the TF receptor.
In addition to confirming the existence of a receptor, these
data also suggest a possible mechanism for receptor-medi-
ated Fe acquisition by the meningococcus. While the Kd of
0.7 ,uM is low relative to values established for eucaryotic
receptors (2, 7), it is typical of some receptors in lower
organisms (29). Since TF is present physiologically at 30
F.M, a concentration far higher than the 1 ,uM saturation
point for both binding and uptake, high-affinity binding ofTF
may be unnecessary for efficient Fe uptake from TF. Our
data suggest that meningococci bind human TF regardless of
whether TF contains Fe; low binding affinity results in high
turnover of TF at the cell surface. This may allow the
meningococcus to sort through the available TF and remove
Fe from ferrated molecules. If the receptor bound Fe-TF
with high affinity, as do human (31) and mouse (30) TF
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Fe would require preferential release of apoTF. This would
be reflected in an attenuated affinity of meningococci for
apoTF, which was not observed. Unlike the situation with
eucaryotic cells, however, TF is not internalized after bind-
ing to pathogenic Neisseria species (1, 18, 28). The correla-
tion between concentrations of Fe-uptake saturation and
binding of TF (1 ,uM) suggests that receptor-mediated bind-
ing of TF may be the rate-limiting step in Fe uptake from
Fe-TF. This idea is supported by the phenotype of FAM38;
an approximately fivefold reduction in apparent receptor
copy number is responsible for at least a 95% reduction in Fe
uptake from TF (8).
Care must be taken in interpreting the 251I-TF binding
data. At infinite dilution, about 10% of bound ligand is shed
after 0.15 times the necessary binding time (2). The washes
performed after binding required significantly longer than
0.15 times the 20-min binding time (which is probably greater
than the necessary binding time). Affinities and copy num-
bers may thus be underestimated. The estimates, however,
describe the relative differences between strains. Moreover,
the existence of reproducible specific binding after the
substantial interval at infinite dilution is a compelling argu-
ment for the presence of a receptor.
Although the dot enzyme assay measures total (including
nonspecific) binding and gives only rough qualitative an-
swers, the similarity in results from the equilibrium 125I-TF-
binding assay suggests that the relatively simple dot enzyme
assay may be a rapid method to screen meningococcal
mutants for TF-binding ability or to screen recombinant
libraries for TF receptor activity. A significant difference in
results with the two binding assays concerned the apparent
affinity of apoTF binding to the receptor. Schryvers and
Morris (27) demonstrated a significant difference between
the abilities of apoTF and 100% Fe-saturated TF to compete
with the binding of HRP-TF, but our 125I-TF assay showed
no difference. This discrepancy was not due to the presence
of contaminating Fe in the 125I-TF assay. TF may be
modified by the bulky HRP in such a way that binding is, for
unknown reasons, less sensitive to competition by apoTF.
Alternatively, the 125I-TF assay may be complicated because
of oxidative damage to TF during iodination. However,
damage from iodination was undetectable by SDS-PAGE
and autoradiography, and 1 ,uM (barely saturating) 125I-TF
supported normal growth of meningococci, indistinguishable
from that with unmodified TF.
Time course experiments showed greater receptor activity
with increasing Fe starvation. This suggests that the receptor
is an FeRP or at least includes an Fe-regulated surface
component. The identity of the receptor is unknown. The
receptor cannot be the 85- or the 95-kDa FeRP, since
FAM38 and FAM41 were equally deficient in receptor
activity despite their differences in expression of these
FeRPs. The 70-kDa FeRP is likely unimportant to the TF
receptor, since FAMli, which lacks the common 70-kDa
FeRP by chemical and immunological criteria (9), demon-
strated wild-type TF receptor activity. Recently, Schryvers
and Morris used TF-affinity chromatography to identify
several meningococcal proteins with apparent specificity for
TF; one of these was about 65 kDa (27a). Our results showed
a 65-kDa protein that bound HRP-TF in a Western blot, but
this protein probably is not necessary for TF receptor
function, since it was much reduced in a mutant (FAM11)
that exhibited normal TF receptor activity. Further experi-
ments are required to establish the identity of the TF
receptor.
ACKNOWLEDGMENTS
This work was supported by Public Health Service grants A123357
(D.W.D.) and A115036 (P.F.S.), both from the National Institute of
Allergy and Infectious Diseases.
In addition, we thank A. Schryvers for communicating the details
of the HRP-TF assay prior to publication. We also thank F.
Archibald, T. Meitzner, V. Tryon, and N. Carbonetti for helpful
discussions; E. West for technical assistance; and L. Brooks for the
preparation of the manuscript.
LITERATURE CITED
1. Archibald, F. S., and I. W. DeVoe. 1979. Removal of iron from
human transferrin by Neisseria meningitidis. FEMS Microbiol.
Lett. 6:159-169.
2. Bennett, J. P., Jr. 1978. Methods in binding studies, p. 57-90. In
H. I. Yamamura et al. (ed.), Neurotransmitter receptor binding.
Raven Press, New York.
3. Black, J. R., D. W. Dyer, M. K. Thompson, and P. F. Sparling.
1986. Human immune response to iron-repressible outer mem-
brane proteins of Neisseria meningitidis. Infect. Immun. 54:
710-713.
4. Brener, D., I. W. DeVoe, and B. E. Holbein. 1981. Increased
virulence of Neisseria meningitidis after in vitro iron-limited
growth at low pH. Infect. Immun. 33:59-66.
5. BulHen, J. J., H. J. Rogers, and E. Griffiths. 1974. Bacterial iron
metabolism in infection and immunity, p. 518-551. In J. B.
Neiland (ed.), Microbial iron metabolism: a comprehensive
treatise. Academic Press, Inc., New York.
6. Burgitt, M. W., S. J. Fairfield, and J. F. Monthony. 1977. A
solid-phase fluorescent immunoassay for the quantitation of the
C4 component of human complement. J. Immunol. Methods.
16:211-219.
7. Burt, D. R. 1978. Criteria for receptor identification, p. 41-55. In
H. I. Yamamura et al. (ed.), Neurotransmitter receptor binding.
Raven Press, New York.
8. Dyer, D. W., W. McKenna, J. P. Woods, and P. F. Sparling.
1987. Isolation by streptonigrin enrichment and characterization
of a transferrin-specific iron uptake mutant of Neisseria menin-
gitidis. Microb. Pathog. 3:351-363.
9. Dyer, D. W., E. P. West, W. McKenna, S. A. Thompson, and
P. F. Sparling. 1988. A pleiotropic iron-uptake mutant of Neis-
seria meningitidis lacks a 70-kilodalton iron-regulated protein.
Infect. Immun. 56:977-983.
10. Frasch, C. E., and M. S. Peppler. 1982. Protection against group
B Neisseria meningitidis disease: preparation of soluble protein
and protein-polysaccharide immunogens. Infect. Immun. 37:
271-280.
11. Holbein, B. E. 1980. Iron-controlled infection with Neisseria
meningitidis in mice. Infect. Immun. 29:886-891.
12. Holbein, B. E. 1981. Enhancement of Neisseria meningitidis
infection in mice by addition of iron bound to transferrin. Infect.
Immun. 34:120-125.
13. Hunter, W. M., and F. C. Greenwood. 1962. Preparation of
iodine-131 labeled human growth hormone of high specific
activity. Nature (London) 194:495-496.
14. Kellogg, D. S., Jr., W. L. Peacock, Jr., W. E. Deacon, L. Brown,
and C. I. Pirkle. 1963. Neisseria gonorrhoeae. I. Virulence
genetically linked to clonal variation. J. Bacteriol. 85:1274-
1279.
15. Laemmli, U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227:680-685.
16. Markwell, M. A. K. 1983. A new solid-state reagent to iodinate
proteins. I. Conditions for the efficient labeling of antiserum.
Anal. Biochem. 125:427-432.
17. Masson, P. L., J. F. Heremans, and C. H. Dive. 1966. An
iron-binding protein common to many external secretions. Clin.
Chim. Acta 14:729-734.
18. McKenna, W. R., P. A. Mickelsen, P. F. Sparling, and D. W.
Dyer. 1988. Iron uptake from lactoferrin and transferrin by
Neisseria gonorrhoeae. Infect. Immun. 56:785-791.
19. Mickelsen, P. A., and P. A. Sparling. 1981. Ability of Neisseria
gonorrhoeae, Neisseria meningitidis, and commensal Neisseria
VOL. 56, 1988
3138 TSAI ET AL.
species to obtain iron from transferrin and iron compounds.
Infect. Immun. 33:555-564.
20. Neilands, J. B. 1981. Microbial iron compounds. Annu. Rev.
Biochem. 50:715-731.
21. Neilands, J. B. 1982. Microbial envelope proteins related to iron.
Annu. Rev. Microbiol. 36:285-309.
22. Norrod, P., and R. P. Williams. 1978. Growth of Neisseria
gonorrhoeae in media deficient in iron without detection of
siderophores. Curr. Microbiol. 1:281-284.
23. Peterson, K. M., and J. F. Alderete. 1987. Iron uptake and
increased intracellular enzyme activity following host lactofer-
rin binding by Trichomonas vaginalis receptors. J. Exp. Med.
160:398-410.
24. Redhead, K., T. Hill, and H. Chart. 1987. Interaction of lacto-
ferrin and transferrins with the outer membrane of Bordetella
pertussis. J. Gen. Microbiol. 133:891-898.
25. Russell, L. M., S. J. Cruz, Jr., and R. K. Holmes. 1984. Genetic
and biochemical evidence for a siderophore-dependent iron
transport system in Corynebacterium diphtheria. Infect. Im-
mun. 45:143-149.
26. Scatchard, G. 1949. The attractions of proteins for small mole-
cules and ions. Ann. N.Y. Acad. Sci. 54:660-672.
27. Schryvers, A. B., and L. J. Morris. 1988. Identification and
characterization of the transferrin receptor from Neisseria men-
ingitidis. Mol. Microbiol. 2:281-288.
27a.Schryvers, A. B., and L. J. Morris. 1988. Identification and
characterization of the human lactoferrin-binding protein from
Neisseria meningitidis. Infect. Immun. 56:1144-1149.
28. Simonson, C., D. Brener, and I. W. DeVoe. 1982. Expression of
a high-affinity mechanism for acquisition of transferrin iron by
Neisseria meningitidis. Infect. Immun. 36:107-113.
29. Tryon, V. V., and J. B. Baseman. 1987. The acquisition of
human lactoferrin by Mycoplasma pneumoniae. Microb. Pa-
thog. 3:437-443.
30. Ventura, M. A., F. Louache, M. Rouis, D. Erlich, S. Goldstein,
U. Testa, and P. Thomopoulos. 1987. Specific modulation of
surface receptors in J774 macrophages by anchorage. Exp. Cell
Res. 170:290-299.
31. Ward, J. H. 1987. The structure, function, and regulation of
transferrin receptors. Invest. Radiol. 22:79-83.
32. Weinberg, E. D. 1978. Iron and infection. Microbiol. Rev. 42:
45-66.
33. West, S. E. H., and P. F. Sparling. 1985. Response of Neisseria
gonorrhoeae to iron limitation: alterations in expression of
membrane proteins without apparent siderophore production.
Infect. Immun. 47:388-394.
34. West, S. E. H., and P. F. Sparling. 1987. Aerobactin utilization
by Neisseria gonorrhoeae and cloning of a genomic DNA
fragment that complements Escherichia coliAhuB mutations. J.
Bacteriol. 169:3414-3421.
INFECT. IMMUN.
